Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI - Free Report) had its price target upped by HC Wainwright from $38.00 to $39.00 in a report issued on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Greenwich LifeSciences' Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences Stock Down 4.4 %

Shares of GLSI traded down $0.46 on Monday, hitting $9.98. 62,962 shares of the stock traded hands, compared to its average volume of 45,289. Greenwich LifeSciences has a 1 year low of $8.06 and a 1 year high of $18.75. The stock's 50 day moving average is $10.68 and its two-hundred day moving average is $12.27. The firm has a market capitalization of $132.47 million, a P/E ratio of -12.47 and a beta of 1.76.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). Research analysts forecast that Greenwich LifeSciences will post -0.8 EPS for the current year.

Insider Buying and Selling at Greenwich LifeSciences

In related news, CEO Snehal Patel purchased 3,600 shares of the firm's stock in a transaction on Monday, April 7th. The shares were bought at an average price of $9.10 per share, for a total transaction of $32,760.00. Following the acquisition, the chief executive officer now directly owns 5,561,602 shares in the company, valued at $50,610,578.20. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders acquired 14,500 shares of company stock worth $129,267 in the last 90 days. 51.67% of the stock is owned by company insiders.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after acquiring an additional 1,008 shares during the period. Brown Brothers Harriman & Co. acquired a new position in shares of Greenwich LifeSciences in the 4th quarter valued at about $45,000. JPMorgan Chase & Co. increased its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after purchasing an additional 4,465 shares in the last quarter. Bank of America Corp DE increased its position in Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after buying an additional 3,168 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.